Ferroptosis – a potential feature underlying neratinib-induced colonic epithelial injury

Nguyen, Triet P. M.; Woods, Susan L.; Secombe, Kate R.; Tang, Simon; Elz, Aurelia S.; Ayton, Scott; Finnie, John; Nagpal, Aadya; Pouliot, Normand; Bowen, Joanne M.

doi:10.1007/s00280-024-04699-9

Ferroptosis – a potential feature underlying neratinib-induced colonic epithelial injury

Original Article
Open access
Published: 13 July 2024

(2024)
Cite this article

Download PDF

You have full access to this open access article

Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Ferroptosis – a potential feature underlying neratinib-induced colonic epithelial injury

Download PDF

Triet P. M. Nguyen^1,12^nAff2,
Susan L. Woods^3,6,
Kate R. Secombe¹,
Simon Tang⁴,
Aurelia S. Elz^1,5,
Scott Ayton^2,12,
John Finnie⁷,
Aadya Nagpal^8,9,11,
Normand Pouliot^8,9,10 &
…
Joanne M. Bowen¹¹^nAff1

Abstract

Purpose

Neratinib, a small-molecule tyrosine kinase inhibitor (TKI) that irreversibly binds to human epidermal growth factor receptors 1, 2 and 4 (HER1/2/4), is an approved extended adjuvant therapy for patients with HER2-amplified or -overexpressed (HER2-positive) breast cancers. Patients receiving neratinib may experience mild-to-severe symptoms of gut toxicity including abdominal pain and diarrhoea. Despite being a highly prevalent complication in gut health, the biological processes underlying neratinib-induced gut injury, especially in the colon, remains unclear.

Methods

Real-time quantitative polymerase chain reaction (RT-qPCR) and histology were integrated to study the effect of, and type of cell death induced by neratinib on colonic tissues collected from female Albino Wistar rats dosed with neratinib (50 mg/kg) daily for 28 days. Additionally, previously published bulk RNA-sequencing and CRISPR-screening datasets on human glioblastoma SF268 cell line and glioblastoma T895 xenograft, and mouse TBCP1 breast cancer cell line were leveraged to elucidate potential mechanisms of neratinib-induced cell death.

Results

The severity of colonic epithelial injury, especially degeneration of surface lining colonocytes and infiltration of immune cells, was more pronounced in the distal colon than the proximal colon. Sequencing showed that apoptotic gene signature was enriched in neratinib-treated SF268 cells while ferroptotic gene signature was enriched in neratinib-treated TBCP1 cells and T895 xenograft. However, we found that ferroptosis, but less likely apoptosis, was a potential histopathological feature underlying colonic injury in rats treated with neratinib.

Conclusion

Ferroptosis is a potential feature of neratinib-induced colonic injury and that targeting molecular machinery governing neratinib-induced ferroptosis may represent an attractive therapeutic approach to ameliorate symptoms of gut toxicity.

Use our pre-submission checklist

Avoid common mistakes on your manuscript.

Introduction

Breast cancer is the most frequently diagnosed type of cancer in women worldwide [1]. Among all subtypes of breast cancer, the aggressive human epidermal growth factor 2-positive (HER2-positive) breast cancer, which is characterised by overexpressed or amplified HER2 receptor, accounts for approximately 20–30% of all annually diagnosed cases [2]. In the past century, patients diagnosed with HER2-amplified or -overexpressed (also referred as HER2-positive) breast cancer were frequently associated with the poorest prognosis and with the highest incidence of brain metastasis [3,4,5,6,7]. However, this is no longer the case following the relatively recent development of novel HER2-targeted therapies, including monoclonal antibody and small-molecule tyrosine kinase inhibitors (TKI), that more precisely target HER2-positive cells to inhibit the activation of downstream signalling while triggering cell death pathways [8].

Orally taken ATP-competitive TKIs, such as the pan-HER-TKI neratinib, have garnered considerable attention in recent years as an effective extended adjuvant HER2-targeted therapy for patients with HER2-positive breast cancers after receiving a combination of chemotherapy and monoclonal antibody trastuzumab [9]. Neratinib treatment significantly improves invasive disease-free survival rate while reducing long-term toxicity and complication rate. Mechanistically, neratinib forms a covalent bond with cysteine residues in the ATP-binding pocket of HER1 (also known as EGFR), HER2 and HER4 receptors to inhibit their downstream canonical Ras/ERK and Akt/mTOR pathways, suppressing cell proliferation, and triggering cell death [10, 11]. A previous study using in vitro HER2-positive breast cancer cell lines, which expressed wild-type oestrogen receptor, such as SKBR3, showed that neratinib treatment repressed the activity of nuclear factor-erythroid factor 2-related factor 2 (NRF2), a master regulator of antioxidant defence, to then promote oxidative-stress-dependent cell death [12]. Oxidative stress is a condition of sustained elevation of intracellular reactive oxygen species (ROS) that potentially leads to reversible and irreversible damage to biomolecules such as lipids, proteins, and nucleic acids [13]. ‘ROS’ is an umbrella term describing a collection of oxygen-derived radicals, such as singlet superoxide (O₂^{• −}) and hydroxyl radical (^•OH), and species, such as hydrogen peroxide (H₂O₂) and lipid peroxide. Strikingly, a recent report from Nagpal and colleagues revealed that, rather than apoptosis as induced by other TKIs, such as lapatinib, neratinib promoted non-apoptotic cell death called ferroptosis in both human (SKBR3) and mouse (TBCP1) HER2-positive breast cancer cell lines [14]. Ferroptosis is a newly discovered type of cell death characterised by perturbed iron and redox homeostasis with excessive lipid peroxidation at phospholipid membrane [15]. Unless the rise of endogenous lipid peroxide is averted such as by the scavenging enzymatic activity of glutathione peroxidase 4 (GPX4), the accumulation of lethal membrane lipid peroxide results in the loss of membrane integrity and ultimately leads to cell death [16].

Despite therapeutic effectiveness against HER2-positive breast cancers, patients receiving neratinib can experience mild to severe symptoms of gut toxicity, such as abdominal pain and diarrhoea, which can lead to early dose reduction or treatment discontinuation [17, 18]. Interestingly, a recent randomised controlled trial conducted by Sonnichsen and colleagues reported that though serum levels of neratinib were higher in patients receiving 240 mg of neratinib once daily (QD) than those receiving 120 mg of neratinib twice daily (BID), patients in the QD group experienced less severe diarrhoea [18]. This suggested that diarrhoea is potentially a consequence of local exposure to neratinib rather than systemic exposure. In support, starting patients on a reduced dose of neratinib for the first two weeks is also associated with greatly reduced levels of diarrhoea and treatment discontinuations [19]. Furthermore, an escalating dose of neratinib resulted in more severe symptoms of gut toxicity observed in our preclinical rat models and other clinical trials [20, 21]. We therefore postulate that inhibition of locally expressed HER receptors in the intestinal epithelial cells which subsequently triggers epithelial cell death is likely a cause of gut toxicity. This is plausible due to the gut epithelium naturally expressing HER receptors and being strongly dependent on HER downstream signalling pathways for cell survival, differentiation, and proliferation [22,23,

Table 2 List of primers used for RT-qPCR experiments

Full size table

RNA-sequencing analysis

RNA-sequencing analysis on previously published datasets was carried out to examine which biological pathways were significantly enriched following neratinib treatment. Processed count tables for protein encoded genes from neratinib-treated mouse TBCP-1 breast cancer and human glioblastoma SF268 and TS895 cell lines were kindly provided by Dr Normand Pouliot (Olivia Newton-John Cancer Research Institute) and Dr Colin Tang (Weill Cornell Medicine) [14, 31]. Differential gene expression between neratinib and vehicle control groups was performed using DESeq2 (v1.38.3) statistical package in R [35]. Unless otherwise stated, a master list of differentially expressed (DE) genes was generated when the P-adjusted value less than 0.05. Subsequently, a list of significantly upregulated genes with log₂FoldChange values above 0.1 was generated from the master DE gene list with P-adjusted values or false discovery rate (FDR) below 0.05. Subsequently, this gene list was inserted into the online database for annotation, visualisation, and integrated discovery (DAVID) bioinformatic resource website for gene ontology (GO) terms and KEGG pathway analyses as previously described [36,37,38]. The computational algorithm used to determine statistical significance of individual pathways was detailed in the original papers [36, 39]. Here, GO terms and KEGG pathways were deemed as significantly enriched with P values below 0.05.

CRISPR-screening analysis

As previously described in Tang et al. [31], a pool CRISPR screen was performed on neratinib-treated SF268 human glioblastoma cell line to identify genes contributing to neratinib sensitivity. A count table of differentially expressed single-guided RNA and an output file of DrugZ were kindly provided by Dr Colin Tang from Weill Cornell Medicine. Using R script publicly available generated by Dr Colin Tang, drugZ rank plot was generated for normalised Z score against sgRNA rank ⁹⁵. The positive or negative normalised Z score of a gene with FDR below 0.05 confers with either neratinib sensitivity or resistance, respectively.

Data analysis and statistics

Descriptions for sample size and statistical tests are detailed in figure legends. Unless otherwise specified, all statistical analyses were carried out using unpaired Student’s t-test in GraphPad Prism 9 (version 9.2.0; USA). Statistical values were reported in mean ± standard error of the mean (mean ± SEM). Statistical significance, which was reported as exact P values, was considered as followed – for all histological assessment, RT-qPCR, gene ontology and KEGG pathway analyses, P values below 0.05 were deemed significant while for differential gene expression and Drug-Z analyses, P-adjusted values, or false discovery rate (FDR) below 0.05 were deemed significant.

Data availability

The data generated in this study are available within the article and its supplementary data files, with further raw data available upon request. Further information and requests for resources should be directed to and will be fulfilled by the corresponding authors, Joanne M. Bowen (joanne.bowen@adelaide.edu.au) and Triet PM. Nguyen(phuminhtrietthomas.nguyen@unimelb.edu.au).

Results

Neratinib-induced injury is spatially located in the rat colon

As previously reported from our group, all rats dosed with neratinib experienced common signs of gut toxicity including weight loss and moderate diarrhoea [32]. To determine the spatial effect of neratinib on the rat colon, we performed histopathological assessment using haematoxylin and eosin (H&E) and immunohistochemical (IHC) staining on proximal and distal colon. Overall, we observed that following neratinib treatment, the most severe morphological damage was found in the distal colon as reflected by a significantly higher histopathological score and increased crypt length (Fig. 1a, b, and c). In sharp contrast, despite a significant increase in proliferative Ki67-positive cells, the proximal colon of neratinib-treated rats only displayed a few, small, focal areas of mild mucosal damage without apparent sign of injury in the surface lining colonocytes expressing carbonic anhydrase 1 (CA1) (Fig. 1a-d).

In the distal colon, degeneration of surface lining CA1⁺ colonocytes with occasional exfoliation of epithelial cells into the lumen leaving a residual denuded surface was observed (Fig. 1a). Migration of flattened, attenuated enterocytes across the denuded mucosal surface was also found which suggested that surviving epithelial cells attempted to cover the surface defects to maintain the integrity of the epithelial lining (Fig. 1a). A significant increase in the proliferative crypt compartment containing Ki67-positive cells further suggested that a reparative mechanism was in place to regenerate the injured surface epithelium (Fig. 1d). A markedly increased inflammatory infiltrate, which primarily comprised of lymphocytes, but also a few granular leukocytes, mostly eosinophils, were observed in the lamina propria layer of the distal colon following the exposure to neratinib compared to vehicle control (Fig. 1a). Together, these histopathological findings appeared to consistent with features of microscopic colitis, specifically lymphocytic colitis [40]. Our current histopathological data collectively substantiated our observations that the injury in the distal colon and its surface lining colonocytes appeared to be more severe than in the proximal colon on day 28 of neratinib treatment.

Enriched gene signatures for apoptosis or ferroptosis may be cell-type specific following neratinib treatment

To gain insight into the biological processes underlying neratinib-induced cell death, we performed comprehensive analyses on differential gene expression, KEGG pathway and GO on previously published RNA-sequencing datasets [14, 31]. These datasets included TBCP-1 cells, a mouse HER2-overexpressing breast cancer cell line capable of metastasising to the brain, treated with neratinib for 24 h, and intracranial human EGFR/HER1-mutant TS895 glioblastoma xenograft treated with neratinib for 3 h [14, 31]. We decided to utilise these datasets for this analysis because of the absence of -omics studies in neratinib-treated healthy colonocytes or at least in colorectal cancer cell lines in vitro. Our KEGG pathway analysis revealed that ferroptotic cell death, which is characterised by perturbed iron homeostasis and lipid peroxidation [41], was significantly enriched in both model systems (Fig. 2a). As a previous study by Nagpal and colleagues also confirmed that ferroptosis was induced by neratinib in HER2-postive human (SKBR3) and mouse (TBCP1) breast cancer cell lines [14], we hypothesised that neratinib-induced ferroptosis might extend beyond the context of breast cancer.

Gene Ontology (GO) analyses for enriched biological processes further uncovered gene signatures involved in autophagy and positive regulation of autophagy among all biological processes in the list of significantly upregulated genes in both neratinib-treated TBCP1 and TS895 cells (Fig. 2b and Suppl. Table 1). Autophagy is a process mediated by the lysosomal pathway [42] and was previously related to the induction of ferroptosis, especially in the form of ferritinophagy [Full size image

We next aimed to determine the presence of ferroptosis by measuring key markers of iron homeostasis and lipid peroxidation. Through IHC staining, we observed a significant reduction of endogenous ferritin heavy chain 1 (FTH1) in the distal colon of rats treated with neratinib (Fig. 3a and c). A significant upregulation of expression of iron absorption gene, Tfrc, and downregulation of iron storage gene, Fth1, measured by RT-qPCR further suggested that neratinib perturbed the pool of intracellular iron storage leading to an increase in cytosolic reactive ferrous (Fe²⁺) ion in the rat colon (Fig. 3d). Although neratinib did not alter gene expression of Gpx4, which encodes a lipid peroxide scavenging enzyme contributing to ferroptotic resistance [16, 46], we found a significant upregulation of gene expression of Acsl4, which esterifies polyunsaturated fatty acids (PUFA) making them competent for ferroptosis, and arachidonate 15-lipoxygenase (Alox15), which directly causes lipid peroxidation [47, 48] (Fig. 3e). Collectively, the current findings support the notion that ferritinophagy-mediated ferroptosis, but not apoptosis, is the potential histopathological feature underlying neratinib-induced colonic epithelial injury.

Discussion

In the present study, we used colonic tissues collected from healthy female Albino Wistar rats orally dosed with neratinib (50 mg/kg) daily for 28 consecutive days as an in vivo model for studying neratinib-induced colonic epithelial injury [20, 32]. Overall, our study reveals that the injury is spatially located predominantly in the distal colon. In particular, the degeneration and morphological changes of CA1-positive colonocytes lining the surface epithelium are more pronounced in the distal colon than in the proximal colon. We further suggest that ferroptosis is a potential histopathological feature underlying neratinib-induced colonic epithelial injury.

The spatial difference in the severity of injury observed in the proximal and distal colon could be explained on the basis of the molecular regionalisation of the colon. Using spatial transcriptomics, a recent study led by Villablanca’s team revealed that the difference in the morphology of the proximal and distal colon was governed by molecular regionalisation of gene expression [49]. They further showed that the severity of dextran sulphate sodium (DSS)-induced injury varying between different regions of the colon was likely due to this pattern. As the morphology of the proximal and distal colon of the rat are distinct as observed in representative H&E-stained sections (Fig. 1a), we suggest that similar to the mouse colon, there might exist a pattern of molecular regionalization that potentially implicated the distal colon as the major site of injury following neratinib treatment. For example, factors that may contribute to the severity of the injury following neratinib treatment could include the different distribution of HER receptors and upregulation of key inflammatory pathways such as JAK-STAT and TNFα pathways between the proximal and distal colon.

Alternatively, since all rats were culled on day 28 of neratinib treatment and a significant increase in proliferative Ki67-positive cells in both proximal and distal colon of rats treated with neratinib was apparent (Fig. 1a and d), we cannot exclude the possibility that mucosal damage may equally occur in both proximal and distal colon and that the proximal colon may possess an intrinsic adaptive mechanism that leads to a more rapid healing rate. This was reflected by a significant increase in Ki67-positive cells with a less severe injury phenotypes in the proximal colon on day 28 of neratinib treatment. Though the current study does not provide a precise explanation for why the injury in the distal colon appears to be more severe than in the proximal colon, it sheds light on the potential consequence of the pathology following neratinib treatment.

Further investigations in rat colon tissues and the integration of published bulk RNA-sequencing analyses revealed that ferritinophagy-mediated ferroptosis may be the underlying feature of not only colon injury, especially in the surface lining colonocytes, but also cell death in the HER2-positive TBCP-1 breast cancer cell line and HER1-mutant TS895 glioblastoma xenografts. However, there are several limitations associated with the current rat models that prevent a conclusive determination that ferroptosis is the causality of neratinib-induced colon injury. Firstly, though the upregulation of gene expression of Acsl4 and Alox15 is usually associated with lipid peroxidation, confirming the presence of lipid peroxide through IHC staining using HNEJ-1 or anti-malondialdehyde (MDA) antibodies are required to further substantiate the findings of ferroptosis [41, 50]. Secondly, a change in Gpx4 gene expression was not observed in the neratinib-treated group. Previous studies found that transcriptional regulation of Gpx4 did not seem to correlate with ferroptosis vulnerability, but rather mRNA translation and post-translational regulation of Gpx4, which leads to insufficient level or dysfunctional GPX4 enzymatic activity, is implicated in susceptibility to ferroptosis [16, 51,52,53]. Indeed, in the TBCP-1 breast cancer cell line, though neratinib did not alter GPX4 protein level, neratinib downregulated SLC3A2 expression and cysteine import. As a result, intracellular level of glutathione was depleted that potentially leads to the loss of scavenging enzymatic activity of GPX4 [54]. Altogether, we suggest that the enzymatic function of GPX4 might have been impeded in rat colon following neratinib treatment and that further research should be carried out to characterise the role of GPX4 in mediating neratinib-induced ferroptosis in the context of gut toxicity.

Finally, the degeneration changes in the morphology of surface lining CA1-positive colonocytes and changes in the expression of several markers of ferroptosis following a single endpoint of neratinib treatment are not sufficient to claim that ferroptosis is induced in colonocytes as a direct consequence of neratinib treatment. First, the degeneration of surface lining epithelial cells could be due to the improper differentiation of stem/progenitor cells that prevents CA1-positive colonocytes from adopting mature phenotypes, such as expressing carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7) [55]. Second, following neratinib treatment, there was a dramatic increase in the infiltration of lymphocytes in the lamina propria and intraepithelial space of the distal colon that suggested a diagnosis of lymphocytic colitis. A common feature of lymphocytic colitis is the infiltration of CD8⁺ lymphocytes. Active immune cells, such as CD8⁺ lymphocytes, are able to stimulate ferroptotic cell death. Two recent studies from Wang et al. [56] and Liao et al. [57] reported that ferroptosis could be induced by active CD8⁺ T cells. Mechanistically, following the release of interferon gamma (IFNγ) from active CD8⁺ T cells and interaction with cognate receptors on melanoma and colon cancer cells, the downstream signalling of IFNγ robustly induced ferroptotic cell death by stimulating the uptake of arachidonic acid and upregulation of ACSL4 while suppressing the expression of SLC7A11, which encodes for system X_c⁻ essential for cysteine uptake [56, 57]. As such, based on the current data collected from a single endpoint on day 28 of neratinib treatment, it is possible that ferroptosis is a consequence of active immune cells, such as CD8⁺ T cells, leading to epithelial cell death following neratinib treatment. Collectively, it is essential for future studies to determine whether (i) mature CEACAM7-positive colonocytes are the major target of neratinib and (ii) the death of surface lining colonocytes is a direct consequence of neratinib treatment or active CD8⁺ T cells.

To address the current gap in our in vivo rat model analysis and to further dissect the underlying mechanism of neratinib-induced colonic cell death, we provide several suggestions to direct future studies. First, several earlier timepoints of neratinib-treated rats is required to (i) assess the injury in both proximal and distal colons and (ii) to confirm whether the population of surface-lining CEACAM7-positive colonocytes is affected following neratinib treatment. Similar to a previous study by Chen and colleagues [50] where the presence of ferroptotic tissue was observed in a mouse model of DSS-induced colitis, to ascertain if ferroptosis is induced and dependent to ferritinophagy in rat colon, rats could be co-treated with neratinib and liproxstatin-1, a potent spiroquinoxalinamine radical trap of lipid peroxide [51], and deferoxamine (DFO) or deferiprone, an iron chelator scavenging reactive ferrous iron [15, 58]. If liprostatin-1 and DFO/deferiprone can substantially mitigate colon injury and signs of gut toxicity in rats treated with neratinib, then ferroptosis is confirmed as the underlying feature of neratinib-induced colon injury.

Second, future studies can potentially utilise in vitro three-dimensional colonic organoids, which can precisely recapitulate the complex heterogeneity of the colonic epithelium, to assess the direct effect of neratinib treatment on colonic epithelial cells avoiding the contribution of the immune system [59,60,61]. Critically, the use of undifferentiated stem and proliferative cells, and differentiated immature and mature colonocytes, organoids derived from both humans and mice are recommended to investigate the effects of neratinib inhibition on the differentiation potential of undifferentiated organoids and cell death of differentiated colonocytes.

In summary, the findings from this study suggest that ferritinophagy-mediated ferroptosis is a potential mechanism of cell death driving neratinib-induced colonic mucosal injury. We hope that our current findings will inspire future research to pursue a thorough mechanistic elucidation of how neratinib induces ferroptosis. An insight into this biological phenomenon may serve as an exciting new platform for future supportive therapies and drug discovery to mitigate gut toxicity while enhancing the efficacy of similar or emerging anti-cancer therapeutics.

Data availability

No datasets were generated or analysed during the current study.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
Article CAS PubMed Google Scholar
Prati R, Apple SK, He J, Gornbein JA, Chang HR (2005) Histopathologic characteristics Predicting HER-2/neu amplification in breast Cancer. Breast J 11(6):433–439
Article CAS PubMed Google Scholar
Altundag K, Bondy ML, Mirza NQ, Kau S-W, Broglio K, Hortobagyi GN, Rivera E (2007) Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 110(12):2640–2647
Article CAS PubMed Google Scholar
Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN (2009) High risk of recurrence for patients with breast Cancer who have human epidermal growth factor receptor 2–Positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34):5700–5706
Article PubMed PubMed Central Google Scholar
Goyette M-A, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault M-P, Johnson RM, Carmeliet P, Basik M, Gaboury L, Muller WJ, Park M, Roux PP, Gratton J-P, Côté J-F (2018) The receptor tyrosine kinase AXL is required at multiple steps of the Metastatic Cascade during HER2-Positive breast Cancer Progression. Cell Rep 23(5):1476–1490
Article CAS PubMed Google Scholar
Harper KL, Sosa MS, Entenberg D, Hosseini H, Cheung JF, Nobre R, Avivar-Valderas A, Nagi C, Girnius N, Davis RJ, Farias EF, Condeelis J, Klein CA, Aguirre-Ghiso JA (2016) Mechanism of early dissemination and metastasis in Her2 + mammary cancer. Nature 540(7634):588–592
Article CAS PubMed PubMed Central Google Scholar
Xue B, Krishnamurthy K, Allred DC, Muthuswamy SK (2013) Loss of Par3 promotes breast cancer metastasis by compromising cell–cell cohesion. Nat Cell Biol 15(2):189–200
Article CAS PubMed Google Scholar
Oh D-Y, Bang Y-J (2020) HER2-targeted therapies — a role beyond breast cancer. Nat Rev Clin Oncol 17(1):33–48
Article CAS PubMed Google Scholar
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688–1700. https://doi.org/10.1016/s1470-2045(17)30717-9
Article CAS PubMed Google Scholar
Truong TH, Ung PM-U, Palde PB, Paulsen CE, Schlessinger A, Carroll KS (2016) Molecular basis for Redox activation of epidermal growth factor receptor kinase. Cell Chem Biology 23:7
Article Google Scholar
Tsou H-R, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK, Shen R, Shi X, Wang Y-F, Upeslacis J, Wissner A (2005) Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor Receptor-2 kinase activity. J Med Chem 48(4):1107–1131
Article CAS PubMed Google Scholar
Fox DB, Garcia NMG, McKinney BJ, Lupo R, Noteware LC, Newcomb R, Liu J, Locasale JW, Hirschey MD, Alvarez JV (2020) NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism. Nat Metab 2(4):318–334
Article CAS PubMed PubMed Central Google Scholar
Sies H, Berndt C, Jones DP (2017) Oxidative stress. Annu Rev Biochem 86:715–748. https://doi.org/10.1146/annurev-biochem-061516-045037
Article CAS PubMed Google Scholar
Nagpal A, Redvers RP, Ling X, Ayton S, Fuentes M, Tavancheh E, Diala I, Lalani A, Loi S, David S, Anderson RL, Smith Y, Merino D, Denoyer D, Pouliot N (2019) Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2 + ve breast cancer metastasis. Breast Cancer Res 21(1):1–19
Article CAS Google Scholar
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, Stockwell BR (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149(5):1060–1072
Article CAS PubMed PubMed Central Google Scholar
Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156(1–2):317–331. https://doi.org/10.1016/j.cell.2013.12.010
Article CAS PubMed PubMed Central Google Scholar
Chen P, Chen F, Zhou B (2019) Risk of gastrointestinal events during neratinib therapy in patients with cancer: a systematic review and meta-analysis of clinical trials. Int J Clin Exp Med 12(4):3546–3557
CAS Google Scholar
Abbas R, Hug BA, Leister C, Sonnichsen D (2012) A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. Cancer Chemother Pharmacol 70(1):191–199. https://doi.org/10.1007/s00280-012-1857-3
Article CAS PubMed Google Scholar
Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz J, Egle D, Pistilli B, Wassermann J, Cheong K, Schnappauf B, Semsek D, Singer CF, Foruzan N, DiPrimeo D, McCulloch L, Hurvitz SA, Barcenas CH (2023) Final findings from the CONTROL trial: strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast. Cancer Breast 67:94–101
PubMed Google Scholar
Secombe KR, Ball IA, Shirren J, Wignall AD, Keefe DM, Bowen JM (2021) Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant. Breast Cancer 28(1):99–109. https://doi.org/10.1007/s12282-020-01133-9
Article PubMed Google Scholar
Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA (2009) A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15(7):2552–2558. https://doi.org/10.1158/1078-0432.Ccr-08-1978
Article CAS PubMed Google Scholar
Abud HE, Chan WH, Jardé T (2021) Source and impact of the EGF family of ligands on intestinal stem cells. Front Cell Dev Biology 9:1–9
Article Google Scholar
Yamaoka T, Yan F, Cao H, Hobbs SS, Dise RS, Tong W, Polk DB (2008) Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis. Proc Natl Acad Sci USA 105(33):11772–11777
Article CAS PubMed PubMed Central Google Scholar
**ang J, Bandura J, Zhang P, ** Y, Reuter H, Edgar BA (2017) EGFR-dependent TOR-independent endocycles support Drosophila gut epithelial regeneration. Nat Communication 8:1–13
Article CAS Google Scholar
Yang Y-P, Ma H, Starchenko A, Huh WJ, Li W, Hickman FE, Zhang Q, Franklin JL, Mortlock DP, Fuhrmann S, Carter BD, Ihrie RA, Coffey RJ (2017) A chimeric egfr protein reporter mouse reveals Egfr localization and trafficking in vivo. Cell Rep 19(6):1257–1267
Article CAS PubMed PubMed Central Google Scholar
Hirsh V, Blais N, Burkes R, Verma S, Croitoru K (2014) Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. Curr Oncol 21(6):329–336. https://doi.org/10.3747/co.21.2241
Article CAS PubMed PubMed Central Google Scholar
Sandhu BK, Tripp JH, Candy DC, Harries JT (1981) Loperamide: studies on its mechanism of action. Gut 22(8):658–662. https://doi.org/10.1136/gut.22.8.658
Article CAS PubMed PubMed Central Google Scholar
Pannemans J, Corsetti M (2018) Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders? Curr Opin Pharmacol 43:53–58. https://doi.org/10.1016/j.coph.2018.08.008
Article CAS PubMed Google Scholar
Hurvitz S, Chan A, Iannotti N, Ibrahim E, Chien J, Chan N, Kellum A, Hansen V, Marx G, Kendall S, Wilkinson M, Castrellon A, Ruiz R, Fang P, Hunt D, Moran S, Olek E, Barcenas C, Rugo H (2018) Abstract P3-14-01: effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2 + early-stage breast cancer: the CONTROL trial. Cancer Res 78(4)
Barcenas CH, Hurvitz SA, Palma JAD, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Saenz JG, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D, Chan A (2020) Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol 31(9):1123–1230
Article Google Scholar
Tang CP, Clark O, Ferrarone JR, Campos C, Lalani AS, Chodera JD, Intlekofer AM, Elemento O, Mellinghoff IK (2022) GCN2 kinase activation by ATP-competitive kinase inhibitors. Nat Chem Biol 18(2):207–215. https://doi.org/10.1038/s41589-021-00947-8
Article CAS PubMed Google Scholar
Secombe KR, Ball IA, Wignall AD, Bateman E, Keefe DM, Bowen JM (2022) Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats. Neoplasia 30:100806. https://doi.org/10.1016/j.neo.2022.100806
Article CAS PubMed PubMed Central Google Scholar
Howarth GS, Francis GL, Cool JC, Xu X, Byard RW, Read LC (1996) Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 126(10):2519–2530. https://doi.org/10.1093/jn/126.10.2519
Article CAS PubMed Google Scholar
Schmittgen Livak analyzing real-time PCR data by the comparative CT method. Nat Protoc 3(6):1101–1108
Love MI, Huber W, Anders S (2014) Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550. https://doi.org/10.1186/s13059-014-0550-8
Article CAS PubMed PubMed Central Google Scholar
Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37(1):1–13. https://doi.org/10.1093/nar/gkn923
Article CAS PubMed Google Scholar
Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44–57. https://doi.org/10.1038/nprot.2008.211
Article CAS PubMed Google Scholar
Magtanong L, Mueller GD, Williams KJ, Billmann M, Chan K, Armenta DA, Pope LE, Moffat J, Boone C, Myers CL, Olzmann JA, Bensinger SJ, Dixon SJ (2022) Context-dependent regulation of ferroptosis sensitivity. Cell Chem Biol 29(9):1409–1418e1406. https://doi.org/10.1016/j.chembiol.2022.06.004
Article CAS PubMed Google Scholar
Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC, Lempicki RA (2007) The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8(9):R183. https://doi.org/10.1186/gb-2007-8-9-r183
Article CAS PubMed PubMed Central Google Scholar
Burke KE, D’Amato M, Ng SC, Pardi DS, Ludvigsson JF, Khalili H (2021) Microscopic colitis. Nat Rev Dis Primers 7(1):39. https://doi.org/10.1038/s41572-021-00273-2
Article PubMed Google Scholar
Stockwell B (2022) Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell 185(14):2401–2421
Article CAS PubMed PubMed Central Google Scholar
Dikic I, Elazar Z (2018) Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol 19(6):349–364. https://doi.org/10.1038/s41580-018-0003-4
Article CAS PubMed Google Scholar
Gao M, Monian P, Pan Q, Zhang W, **ang J, Jiang X (2016) Ferroptosis is an autophagic cell death process. Cell Res 26(9):1021–1032
Article CAS PubMed PubMed Central Google Scholar
Hou W, **e Y, Song X, Sun X, Lotze MT, Zeh HJ, Kang R, Tang D (2016) Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12(8):1425–1428
Article CAS PubMed PubMed Central Google Scholar
Dixon SJ, Pratt DA (2023) Ferroptosis: a flexible constellation of related biochemical mechanisms. Mol Cell. https://doi.org/10.1016/j.molcel.2023.03.005
Article PubMed PubMed Central Google Scholar
Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR (2016) Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci USA 113(34):E4966–4975. https://doi.org/10.1073/pnas.1603244113
Article CAS PubMed PubMed Central Google Scholar
Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, Prokisch H, Trümbach D, Mao G, Qu F, Bayir H, Füllekrug J, Scheel CH, Wurst W, Schick JA, Kagan VE, Angeli JP, Conrad M (2017) ACSL4 dictates ferroptosis sensitivity by sha** cellular lipid composition. Nat Chem Biol 13(1):91–98. https://doi.org/10.1038/nchembio.2239
Article CAS PubMed Google Scholar
Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, Tyurin VA, Anthonymuthu TS, Kapralov AA, Amoscato AA, Mikulska-Ruminska K, Shrivastava IH, Kenny EM, Yang Q, Rosenbaum JC, Sparvero LJ, Emlet DR, Wen X, Minami Y, Qu F, Watkins SC, Holman TR, VanDemark AP, Kellum JA, Bahar I, Bayır H, Kagan VE (2017) PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell 171(3):628–641e626. https://doi.org/10.1016/j.cell.2017.09.044
Article CAS PubMed PubMed Central Google Scholar
Parigi SM, Larsson L, Das S, Ramirez Flores RO, Frede A, Tripathi KP, Diaz OE, Selin K, Morales RA, Luo X, Monasterio G, Engblom C, Gagliani N, Saez-Rodriguez J, Lundeberg J, Villablanca EJ (2022) The spatial transcriptomic landscape of the healing mouse intestine following damage. Nat Commun 13(1):828. https://doi.org/10.1038/s41467-022-28497-0
Article CAS PubMed PubMed Central Google Scholar
Chen Y, Zhang P, Chen W, Chen G (2020) Ferroptosis mediated DSS-induced ulcerative colitis associated with Nrf2/HO-1 signaling pathway. Immunol Lett 225:9–15. https://doi.org/10.1016/j.imlet.2020.06.005
Article CAS PubMed Google Scholar
Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, Basavarajappa D, Rådmark O, Kobayashi S, Seibt T, Beck H, Neff F, Esposito I, Wanke R, Förster H, Yefremova O, Heinrichmeyer M, Bornkamm GW, Geissler EK, Thomas SB, Stockwell BR, O’Donnell VB, Kagan VE, Schick JA, Conrad M (2014) Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 16(12):1180–1191. https://doi.org/10.1038/ncb3064
Article CAS PubMed Google Scholar
Liu H, Forouhar F, Lin AJ, Wang Q, Polychronidou V, Soni RK, **a X, Stockwell BR (2022) Small-molecule allosteric inhibitors of GPX4. Cell Chem Biol 29(12):1680–1693e1689. https://doi.org/10.1016/j.chembiol.2022.11.003
Article CAS PubMed PubMed Central Google Scholar
Zhao J, Jia Y, Mahmut D, Deik AA, Jeanfavre S, Clish CB, Sankaran VG (2023) Human hematopoietic stem cell vulnerability to ferroptosis. Cell 186(4):732–747e716. https://doi.org/10.1016/j.cell.2023.01.020
Article CAS PubMed PubMed Central Google Scholar
Nagpal A, Needham K, Lane DJR, Ayton S, Redvers RP, John M, Selistre-de-Araujo HS, Denoyer D, Pouliot N (2023) Integrin αvβ3 is a master regulator of resistance to TKI-induced ferroptosis in HER2-positive breast cancer. Cancers (Basel) 15(4). https://doi.org/10.3390/cancers15041216
Kanke M, Kennedy Ng MM, Connelly S, Singh M, Schaner M, Shanahan MT, Wolber EA, Beasley C, Lian G, Jain A, Long MD, Barnes EL, Herfarth HH, Isaacs KL, Hansen JJ, Kapadia M, Guillem JG, Feschotte C, Furey TS, Sheikh SZ, Sethupathy P (2022) Single-cell analysis reveals unexpected Cellular changes and transposon expression signatures in the Colonic epithelium of treatment-Naïve adult Crohn’s disease patients. Cell Mol Gastroenterol Hepatol 13(6):1717–1740. https://doi.org/10.1016/j.jcmgh.2022.02.005
Article CAS PubMed PubMed Central Google Scholar
Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, **a H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W (2019) CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569(7755):270–274. https://doi.org/10.1038/s41586-019-1170-y
Article CAS PubMed PubMed Central Google Scholar
Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y, Sell A, Wei S, Grove S, Johnson JK, Kennedy PD, Gijón M, Shah YM, Zou W (2022) CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell 40(4):365–378e366. https://doi.org/10.1016/j.ccell.2022.02.003
Article CAS PubMed PubMed Central Google Scholar
Ablin J, Shalev O, Okon E, Karmeli F, Rachmilewitz D (1999) Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats. Inflamm Bowel Dis 5(4):253–261. https://doi.org/10.1097/00054725-199911000-00003
Article CAS PubMed Google Scholar
Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459(7244):262–265. https://doi.org/10.1038/nature07935
Article CAS PubMed Google Scholar
Sato T, Stange DE, Ferrante M, Vries RGJ, Es JHV, Brink SVd, Houdt WJV, Pronk A, Gorp JV, Siersema PD, Clevers H (2011) Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141(5):1762–1772
Article CAS PubMed Google Scholar
Yin X, Farin HF, Es JHv, Clevers H, Langer R, Karp JM (2014) Niche-independent high-purity cultures of Lgr5 + intestinal stem cells and their progeny. Nat Methods 11(1):106–112
Article CAS PubMed Google Scholar
Al-Dasooqi N, Bowen JM, Gibson RJ, Logan RM, Stringer AM, Keefe DM (2011) Selection of housekee** genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemotherapy 57(1):43–53. https://doi.org/10.1159/000321477
Article CAS PubMed Google Scholar

Download references

Acknowledgements

We thank Adelaide Microscopy, especially Dr Agatha Labrinidis, for providing advice on imaging and analysis. We thank Puma Biotechnology for kindly providing neratinib maleate and funding this project. We thank Dr Senthil Arumugam, Monash Biomedicine Discovery Institute, for helpful discussion. Triet PM. Nguyen was supported by Master of Philosophy (No Honours) Scholarship, The University of Adelaide, Australia.

Funding

Open Access funding enabled and organized by CAUL and its Member Institutions

Author information

Joanne M. Bowen
Present address: School of Biomedicine, The University of Adelaide, Adelaide, South Australia, Australia
Triet P. M. Nguyen
Present address: The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia

Authors and Affiliations

School of Biomedicine, The University of Adelaide, Adelaide, South Australia, Australia
Triet P. M. Nguyen, Kate R. Secombe & Aurelia S. Elz
The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia
Scott Ayton
Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
Susan L. Woods
School of Life and Environmental Sciences, The University of Sydney, Sydney, Australia
Simon Tang
Clinical and Health Sciences, University of South Australia, Adelaide, Australia
Aurelia S. Elz
Precision Cancer Medicine, South Australian Health and Medical Research Institute, Adelaide, SA, Australia
Susan L. Woods
Discipline of Anatomy and Pathology, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia
John Finnie
Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia
Aadya Nagpal & Normand Pouliot
School of Cancer Medicine, La Trobe University, Bundoora, VIC, Australia
Aadya Nagpal & Normand Pouliot
Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, Australia
Normand Pouliot
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, 3000, Australia
Aadya Nagpal & Joanne M. Bowen
Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia
Triet P. M. Nguyen & Scott Ayton

Authors

Triet P. M. Nguyen
View author publications
You can also search for this author in PubMed Google Scholar
Susan L. Woods
View author publications
You can also search for this author in PubMed Google Scholar
Kate R. Secombe
View author publications
You can also search for this author in PubMed Google Scholar
Simon Tang
View author publications
You can also search for this author in PubMed Google Scholar
Aurelia S. Elz
View author publications
You can also search for this author in PubMed Google Scholar
Scott Ayton
View author publications
You can also search for this author in PubMed Google Scholar
John Finnie
View author publications
You can also search for this author in PubMed Google Scholar
Aadya Nagpal
View author publications
You can also search for this author in PubMed Google Scholar
Normand Pouliot
View author publications
You can also search for this author in PubMed Google Scholar
Joanne M. Bowen
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

T.P.M.N. designed, performed, and analysed all biological experiments; K.R.S. performed in vivo rat study; A.S.E. performed tissue staining and analysis; J.F. assessed histopathology of rat tissues; S.A. advised on ferroptotic experiments; T.P.M.N. and S.T. analysed bulk RNA-sequencing and CRISPR-screening data; N.P. and A.N performed RNA-sequencing on TBCP-1 cells and input RNA-sequencing analysis; T.P.M.N., S.L.W., and J.M.B. wrote and edited the manuscript with inputs from all authors. All authors read and edited the final manuscript. J.M.B and S.L.W. supervised the study. J.M.B. designed the original rat study.

Corresponding authors

Correspondence to Triet P. M. Nguyen or Joanne M. Bowen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Nguyen, T.P.M., Woods, S.L., Secombe, K.R. et al. Ferroptosis – a potential feature underlying neratinib-induced colonic epithelial injury. Cancer Chemother Pharmacol (2024). https://doi.org/10.1007/s00280-024-04699-9

Download citation

Received: 19 December 2023
Accepted: 05 July 2024
Published: 13 July 2024
DOI: https://doi.org/10.1007/s00280-024-04699-9

Keywords

Use our pre-submission checklist

Avoid common mistakes on your manuscript.

Ferroptosis – a potential feature underlying neratinib-induced colonic epithelial injury

Abstract

Purpose

Methods

Results

Conclusion

Introduction

RNA-sequencing analysis

CRISPR-screening analysis

Data analysis and statistics

Data availability

Results

Neratinib-induced injury is spatially located in the rat colon

Enriched gene signatures for apoptosis or ferroptosis may be cell-type specific following neratinib treatment

Discussion

Data availability

References

Acknowledgements

Funding

Author information

Authors and Affiliations

Contributions

Corresponding authors

Ethics declarations

Competing interests

Additional information

Publisher’s Note

Electronic supplementary material

Supplementary Material 1

Rights and permissions

About this article

Cite this article

Share this article

Keywords

Search

Navigation